The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Final analysis of KEYNOTE-585: pembrolizumab and chemotherapy in G/GEJ cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the final analysis of the Phase III KEYNOTE-585 trial (NCT03221426), which assessed perioperative pembrolizumab plus chemotherapy versus placebo plus chemotherapy in untreated, locally advanced, resectable gastric and gastroesophageal junction (G/GEJ) cancer. While median event-free survival (EFS) and overall survival (OS) showed trends favoring pembrolizumab plus chemotherapy, the results were not statistically significant. Safety outcomes were consistent across both treatment arms. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding – Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
